Pharmacological management of pancreatitis.

[1]  J. Kountouras,et al.  Intravenous N-acetylcysteine does not prevent post-ERCP pancreatitis. , 2005, Gastrointestinal endoscopy.

[2]  S. Chari,et al.  Protease inhibitors in acute pancreatitis: lessons from the bench and failed clinical trials. , 2005, Gastroenterology.

[3]  Y. Shiratori,et al.  Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  W. Willis,et al.  The role of mast cells in the pathogenesis of pain in chronic pancreatitis , 2005, BMC gastroenterology.

[5]  M. Steer,et al.  Protection against acute pancreatitis by activation of protease-activated receptor-2. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[6]  T. Fukui,et al.  Treatment of acute pancreatitis with protease inhibitors: a meta-analysis , 2004, European journal of gastroenterology & hepatology.

[7]  P. Pasricha,et al.  Trypsin mediates nociception via the proteinase-activated receptor 2: a potentially novel role in pancreatic pain. , 2004, Gastroenterology.

[8]  A. Kingsnorth,et al.  A double-blind placebo-controlled trial of a leukotriene receptor antagonist in chronic pancreatitis in humans. , 2004, Journal of hepato-biliary-pancreatic surgery.

[9]  A. Andriulli,et al.  Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  Min Goo Lee,et al.  Protease-activated receptor 2 exerts local protection and mediates some systemic complications in acute pancreatitis. , 2004, Gastroenterology.

[11]  P. Ruszniewski,et al.  Efficacy of Lanreotide 30 mg on Prevention of Pain Relapse after Oral Refeeding in Patients with Necrotizing Acute Pancreatitis , 2004, Pancreatology.

[12]  E. G. Hahn,et al.  Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. , 2004, Gastrointestinal endoscopy.

[13]  R. Sandler,et al.  Digestive and liver diseases statistics, 2004. , 2004, Gastroenterology.

[14]  G. Sakorafas,et al.  Can somatostatin prevent post‐ERCP pancreatitis? Results of a randomized controlled trial , 2004, Journal of gastroenterology and hepatology.

[15]  W. Chey,et al.  Botulinum toxin injection after biliary sphincterotomy. , 2004, Endoscopy.

[16]  G. Ginsberg,et al.  The effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis. , 2004, Gastrointestinal endoscopy.

[17]  D. Whitcomb.  Acute pancreatitis: Molecular biology update , 2003, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract.

[18]  G. Costamagna,et al.  Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. , 2003 .

[19]  R. Carter,et al.  Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. , 2003, Gastroenterology.

[20]  Michelle A. Anderson,et al.  Complications of ERCP. , 2003, Gastrointestinal endoscopy.

[21]  A. Siriwardena,et al.  Intravenous n‐acetylcysteine, ascorbic acid and selenium‐based anti‐oxidant therapy in severe acute pancreatitis , 2003, Scandinavian journal of gastroenterology.

[22]  A. Andriulli,et al.  Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. , 2002, Gastrointestinal endoscopy.

[23]  F. Prat,et al.  Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study. , 2002, Gastrointestinal endoscopy.

[24]  Ji yao Wang,et al.  Ulinastatin in the treatment of acute pancreatitis: A multicenter clinical trial , 2002 .

[25]  S. Raptis,et al.  Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial. , 2002, Gastrointestinal Endoscopy.

[26]  P. Pasricha,et al.  The Proteinase-Activated Receptor 2 Is Involved in Nociception , 2001, The Journal of Neuroscience.

[27]  P. Edwards,et al.  Prospective randomized double‐blind placebo‐controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography‐induced pancreatitis , 2001, The British journal of surgery.

[28]  A. Budzyńska,et al.  A Prospective, Randomized, Placebo-Controlled Trial of Prednisone and Allopurinol in the Prevention of ERCP-Induced Pancreatitis , 2001, Endoscopy.

[29]  O. Moine,et al.  Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. , 2001, Gastroenterology.

[30]  D. Whitcomb.  Hereditary pancreatitis: new insights into acute and chronic pancreatitis , 1999, Gut.

[31]  J. Hoxie,et al.  Interactions of Mast Cell Tryptase with Thrombin Receptors and PAR-2* , 1997, The Journal of Biological Chemistry.

[32]  M. Gorry,et al.  Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene , 1996, Nature Genetics.

[33]  A. Mariani,et al.  Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group. , 1996, The New England journal of medicine.

[34]  S. Coughlin,et al.  Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. , 1996, The Biochemical journal.

[35]  B. Strömbeck,et al.  Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2. , 1995, European journal of biochemistry.

[36]  Y. Tamura,et al.  Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r-, and C1 esterase. , 1977, Biochimica et biophysica acta.

[37]  O. Merino,et al.  Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: A randomized double-blind trial. , 2003, Gastrointestinal endoscopy.

[38]  S. Fan,et al.  Title Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures : A randomised controlled trial , 2003 .

[39]  T. Horie,et al.  Fatal cases of gabexate mesilate-induced anaphylaxis. , 2002, International journal of clinical pharmacology research.

[40]  A. Andriulli,et al.  Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. , 2000, Gastrointestinal endoscopy.